HFNC combined moxifloxacin solution nebulization in the treatment of patients with COPD and type Ⅱ respiratory failure
Objective To explore the efficacy of high-flow nasal cannula(HFNC)oxygen therapy combined with moxifloxacin solution nebulization in patients with chronic obstructive pulmonary disease(COPD)and type Ⅱ respiratory failure.Methods The study included 86 patients with COPD and type Ⅱ respiratory failure treated.Patients were divided into groups using a random method,with odd numbers assigned to the control group(n=43)receiving HFNC oxygen therapy alone,and even numbers assigned to the treatment group(n=43)receiving HFNC oxygen therapy combined with moxifloxacin solution nebulization.The two groups were compared before and after treatment in terms of 6-minute walk distance(6 MWD),respiratory function accessed by Modified Medical Research Council Dyspnea Scale(MMRC),quality of life accessed by Chronic Obstructive Pulmonary Disease Assessment Test(CAT),blood gas indicators included arterial oxygen tension(PaO2)and arterial carbon dioxide tension(PaCO2),serum inflammatory markers included plasma endothelin-1(EF-1),tissue inhibitor of metalloproteinases-1(TIMP-1),matrix metalloproteinase-9(MMP-9),lung function accessed with forced expiratory volume in the first second(FEV1),ratio of FEV1 to forced vital capacity(FEV1/FVC),and oxidative stress markers in-cluded malondialdehyde(MDA),superoxide dismutase(SOD).Results After treatment,the treatment group showed significant improve-ments in 6MWD,MMRC score,CAT score,PaO2,FEV1,FEV1/FVC,and reductions in PaCO2,EF-1,TIMP-1,MMP-9,and MDA levels,with increased SOD levels compared to the control group(P＜0.05).Conclusion The application of HFNC combined with moxifloxacin solution nebulization in patients with COPD and type Ⅱ respiratory failure can significantly improve patients'exercise capacity,respiratory function,quality of life,blood gas indicators,and lung function,while reducing inflammatory responses and oxidative stress.
万方数据
维普
